Articles tagged with "chimeric antigen receptor T (CAR-T) cells"

mRNA CAR T Cell Therapy Receives FDA’s Rare Pediatric Designation to Treat Juvenile Dermatomyositis

Michele B. Kaufman, PharmD, BCGP | January 30, 2025

FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.

CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier

Jason Liebowitz, MD, FACR | July 2, 2024

Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.

Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report

Mass General Hospital Rheumatology Fellowship Program: Guy Katz, MD; Ian Cooley, MD; Duncan Moore, MD; Jacquelyn Nestor, MD, PhD; & Steven Witte, MD, PhD | February 8, 2022

CD19 chimeric antigen receptor T (CAR-T) cell therapies may have the potential to treat rheumatic diseases in which current therapeutic options are limited, such as lupus, interstitial lung disease and systemic sclerosis.